Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Clinical criteria: Treatment Phase: Induction treatment The condition must have relapsed, or be refractory to, at least two prior systemic therapies, AND Patient must have a WHO performance status of no higher than 2, AND Patient must have previously received treatment with chimeric antigen receptor-T (CAR-T) cell therapy for this condition; OR Patient must be currently unable to receive treatment with CAR-T cell therapy for this condition, AND Patient must not be eligible for stem cell transplantation, AND Patient must not have received prior treatment with a PBS-subsidised CD20xCD3 bispecific monoclonal antibody, AND The treatment must be discontinued in patients who experience disease progression whilst on treatment. Prior systemic therapy may include autologous stem cell transplant. Definition of patients unable to receive treatment with CAR-T cell therapy for this condition include geographical, psychosocial, clinical ineligibility or urgency.
“Epcoritamab is a humanised IgG1-bispecific antibody that binds to a specific extracellular epitope of CD20 on B cells and to CD3 on T cells.”
“The population PK model-derived geometric mean half-life of full dose epcoritamab (48 mg) ranged from 22 to 25 days based on frequency of dosing.”
“Elevation of certain proinflammatory cytokines by EPKINLY may suppress CYP450 enzyme activities.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.